SoCal's Vical Terminates 54% of Workforce to Focus Resources on Two Clinical Programs Post author:Sam Post published:January 30, 2018 Post category:BioPharma Vical announced its restructuring late Tuesday. Source: BioSpace You Might Also Like Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017 Amniox Medical Obtains Federal Supply Schedule Contract For NEOX And CLARIX Product Lines April 16, 2017 Takeda's $5 Billion Bet on Ariad Pays Off With Accelerated Approval of Lung Cancer Med April 30, 2017
Amgen-Backed Immatics Lands $58 Million To Develop T-Cell Receptor Based Immunotherapies October 3, 2017
Amniox Medical Obtains Federal Supply Schedule Contract For NEOX And CLARIX Product Lines April 16, 2017
Takeda's $5 Billion Bet on Ariad Pays Off With Accelerated Approval of Lung Cancer Med April 30, 2017
